This is supported by a case report where we described a severe asthmatic treated with mepolizumab had worsening of symptoms, and molecular analysis revealed increased anti-EPX and IL-5+ILC2s, suggesting that increased Th2 signaling leads to activation of IL-5-producing ILC2s and subsequent eosinophilia (Mukherjee et al., 2017). Here, IL5 is linked to Increased total eosinophil count.